Dyne Therapeutics (DYN) Stock Forecast & Price Target

Compare

333 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DYN Analyst Ratings

Strong Buy

13 Buy

2 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Dyne

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DYN Stock 12 Month Forecast

Average Price Target

$39.07

▲(288.76%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $39.07 with a high forecast of $66.00 and a low forecast of $10.00. The average price target represents a 288.76% change from the last price of $10.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","67":"$67","22.75":"$22.8","37.5":"$37.5","52.25":"$52.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$66.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,22.75,37.5,52.25,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.7,16.799999999999997,20.9,25,29.099999999999998,33.2,37.3,41.39999999999999,45.5,49.599999999999994,53.7,57.8,61.89999999999999,{"y":66,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.7,14.728461538461538,16.756923076923076,18.785384615384615,20.813846153846153,22.842307692307692,24.87076923076923,26.89923076923077,28.927692307692308,30.956153846153846,32.98461538461538,35.01307692307692,37.041538461538465,{"y":39.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.7,12.492307692307692,12.284615384615384,12.076923076923077,11.869230769230768,11.661538461538461,11.453846153846154,11.246153846153845,11.038461538461538,10.830769230769231,10.623076923076923,10.415384615384616,10.207692307692307,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.88,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.49,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$66.00

Average Price Target$39.07

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Catherine NovackJonesTrading

JonesTrading

$30

Buy

198.51%

Upside

Initiated

06/25/25

Dyne Therapeutics initiated with a Buy at JonesResearchDyne Therapeutics initiated with a Buy at JonesResearch

William PickeringBernstein

Bernstein

$13

Hold

29.35%

Upside

Initiated

06/24/25

Dyne Therapeutics (DYN) Receives a Hold from Bernstein

Tessa RomeroJ.P. Morgan

J.P. Morgan

$14→$10

Hold

-0.50%

Downside

Reiterated

06/23/25

J.P. Morgan Sticks to Their Hold Rating for Dyne Therapeutics (DYN)

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$13.82→$66

Buy

556.72%

Upside

Reiterated

06/23/25

Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus

Brian SkorneyRobert W. Baird

Robert W. Baird

$46→$32

Buy

218.41%

Upside

Reiterated

06/18/25

Dyne Therapeutics price target lowered to $32 from $46 at BairdDyne Therapeutics price target lowered to $32 from $46 at Baird

Keay NakaeChardan Capital

Chardan Capital

$50

Buy

397.51%

Upside

Reiterated

06/17/25

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

Ananda GhoshH.C. Wainwright

H.C. Wainwright

$38

Buy

278.11%

Upside

Reiterated

06/17/25

Positive Outlook for Dyne Therapeutics: Buy Rating Justified by Promising DYNE-101 Trial Results and Strategic Moves

Michael UlzMorgan Stanley

Morgan Stanley

$52

Buy

417.41%

Upside

Reiterated

06/17/25

Dyne Therapeutics' DYNE-101 Gains Momentum with FDA Breakthrough Designation and Optimized Clinical Trials

Kostas BiliourisBMO Capital

BMO Capital

$50

Buy

397.51%

Upside

Assigned

06/16/25

Dyne Therapeutics: Strategic Advancements and Promising Clinical Data Drive Buy Rating

Martin AusterRaymond James

Raymond James

$37

Buy

268.16%

Upside

Initiated

06/10/25

Dyne Therapeutics assumed with an Outperform at Raymond JamesDyne Therapeutics assumed with an Outperform at Raymond James

Andreas ArgyridesOppenheimer

Oppenheimer

$60→$34

Buy

238.31%

Upside

Initiated

06/02/25

Dyne Therapeutics assumed with an Outperform at OppenheimerDyne Therapeutics assumed with an Outperform at Oppenheimer

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$46

Buy

357.71%

Upside

Initiated

05/29/25

Dyne Therapeutics (DYN) Receives a Buy from Evercore ISI

Louise ChenScotiabank

Scotiabank

$50

Buy

397.51%

Upside

Reiterated

05/09/25

Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), Argenx Se (ARGX)

Luca IssiRBC Capital

RBC Capital

$36→$30

Buy

198.51%

Upside

Reiterated

05/08/25

RBC Capital Keeps Their Buy Rating on Dyne Therapeutics (DYN)

Edward TenthoffPiper Sandler

Piper Sandler

$48

Buy

377.61%

Upside

Reiterated

04/14/25

Dyne Therapeutics (DYN) Receives a Buy from Piper Sandler

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Catherine NovackJonesTrading

JonesTrading

$30

Buy

198.51%

Upside

Initiated

06/25/25

Dyne Therapeutics initiated with a Buy at JonesResearchDyne Therapeutics initiated with a Buy at JonesResearch

William PickeringBernstein

Bernstein

$13

Hold

29.35%

Upside

Initiated

06/24/25

Dyne Therapeutics (DYN) Receives a Hold from Bernstein

Tessa RomeroJ.P. Morgan

J.P. Morgan

$14→$10

Hold

-0.50%

Downside

Reiterated

06/23/25

J.P. Morgan Sticks to Their Hold Rating for Dyne Therapeutics (DYN)

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$13.82→$66

Buy

556.72%

Upside

Reiterated

06/23/25

Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus

Brian SkorneyRobert W. Baird

Robert W. Baird

$46→$32

Buy

218.41%

Upside

Reiterated

06/18/25

Dyne Therapeutics price target lowered to $32 from $46 at BairdDyne Therapeutics price target lowered to $32 from $46 at Baird

Keay NakaeChardan Capital

Chardan Capital

$50

Buy

397.51%

Upside

Reiterated

06/17/25

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

Ananda GhoshH.C. Wainwright

H.C. Wainwright

$38

Buy

278.11%

Upside

Reiterated

06/17/25

Positive Outlook for Dyne Therapeutics: Buy Rating Justified by Promising DYNE-101 Trial Results and Strategic Moves

Michael UlzMorgan Stanley

Morgan Stanley

$52

Buy

417.41%

Upside

Reiterated

06/17/25

Dyne Therapeutics' DYNE-101 Gains Momentum with FDA Breakthrough Designation and Optimized Clinical Trials

Kostas BiliourisBMO Capital

BMO Capital

$50

Buy

397.51%

Upside

Assigned

06/16/25

Dyne Therapeutics: Strategic Advancements and Promising Clinical Data Drive Buy Rating

Martin AusterRaymond James

Raymond James

$37

Buy

268.16%

Upside

Initiated

06/10/25

Dyne Therapeutics assumed with an Outperform at Raymond JamesDyne Therapeutics assumed with an Outperform at Raymond James

Andreas ArgyridesOppenheimer

Oppenheimer

$60→$34

Buy

238.31%

Upside

Initiated

06/02/25

Dyne Therapeutics assumed with an Outperform at OppenheimerDyne Therapeutics assumed with an Outperform at Oppenheimer

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$46

Buy

357.71%

Upside

Initiated

05/29/25

Dyne Therapeutics (DYN) Receives a Buy from Evercore ISI

Louise ChenScotiabank

Scotiabank

$50

Buy

397.51%

Upside

Reiterated

05/09/25

Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), Argenx Se (ARGX)

Luca IssiRBC Capital

RBC Capital

$36→$30

Buy

198.51%

Upside

Reiterated

05/08/25

RBC Capital Keeps Their Buy Rating on Dyne Therapeutics (DYN)

Edward TenthoffPiper Sandler

Piper Sandler

$48

Buy

377.61%

Upside

Reiterated

04/14/25

Dyne Therapeutics (DYN) Receives a Buy from Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dyne Therapeutics

1 Month

xxx

Success Rate

7/14 ratings generated profit

Average Return

+3.61%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.61% per trade.

3 Months

xxx

Success Rate

3/6 ratings generated profit

Average Return

-3.92%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -3.92% per trade.

1 Year

Edward TenthoffPiper Sandler

Success Rate

9/17 ratings generated profit

Average Return

+20.14%

reiterated a buy rating 3 months ago

Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +20.14% per trade.

2 Years

xxx

Success Rate

7/17 ratings generated profit

Average Return

+53.05%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of +53.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DYN Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DYN has received 19 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. DYN average Analyst price target in the past 3 months is 39.07.

Each month's total comprises the sum of three months' worth of ratings.

DYN Financial Forecast

DYN Earnings Forecast

Next quarter’s earnings estimate for DYN is -$0.94 with a range of -$1.14 to -$0.62. The previous quarter’s EPS was -$1.05. DYN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year DYN has Outperformed its overall industry.

No data currently available

DYN Sales Forecast

Next quarter’s sales forecast for DYN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DYN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year DYN has Preformed in-line its overall industry.

DYN Stock Forecast FAQ

What is DYN’s average 12-month price target, according to analysts?

Based on analyst ratings, Dyne Therapeutics’s 12-month average price target is 39.07.

What is DYN’s upside potential, based on the analysts’ average price target?

Dyne Therapeutics has 288.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DYN a Buy, Sell or Hold?

Dyne Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.

What is Dyne Therapeutics’s price target?

The average price target for Dyne Therapeutics is 39.07. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $66.00 ,the lowest forecast is $10.00. The average price target represents 288.76% Increase from the current price of $10.05.

What do analysts say about Dyne Therapeutics?

Dyne Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of DYN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Dyne Therapeutics (DYN) Stock Forecast & Price Target

DYN Analyst Ratings

DYN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dyne Therapeutics

DYN Analyst Recommendation Trends

DYN Financial Forecast

DYN Earnings Forecast

DYN Sales Forecast

DYN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts